128 related articles for article (PubMed ID: 30868899)
1. ASXL1 gene alterations in patients with isolated 20q deletion.
Brezinova J; Sarova I; Svobodova K; Lhotska H; Ransdorfova S; Izakova S; Pavlistova L; Lizcova L; Skipalova K; Hodanova L; Markova J; Zemanova Z; Cermak J; Jonasova A; Michalova K
Neoplasma; 2019 Jul; 66(4):627-630. PubMed ID: 30868899
[TBL] [Abstract][Full Text] [Related]
2. Fusion of the additional sex combs like 1 and teashirt zinc finger homeobox 2 genes resulting from ider(20q) aberration in a patient with myelodysplastic syndrome.
Brezinova J; Sarova I; Buryova H; Markova J; Ransdorfova S; Izakova S; Kostylkova K; Soukupova J; Zemanova Z; Michalova K
Br J Haematol; 2014 Jan; 164(1):153-5. PubMed ID: 24117282
[No Abstract] [Full Text] [Related]
3. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
[TBL] [Abstract][Full Text] [Related]
4. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
[TBL] [Abstract][Full Text] [Related]
5. Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes.
Saunders K; Czepulkowski B; Sivalingam R; Hayes JP; Aldouri M; Sekhar M; Cummins M; Ho A; Mufti GJ
Cancer Genet Cytogenet; 2005 Jan; 156(2):154-7. PubMed ID: 15642396
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of del(20q) in patients with hematological malignancies.
Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
[TBL] [Abstract][Full Text] [Related]
8. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
[TBL] [Abstract][Full Text] [Related]
9. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
10. Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
Courville EL; Singh C; Yohe S; Linden MA; Naemi K; Berger M; Ustun C; McKenna RW; Dolan M
Am J Clin Pathol; 2016 Apr; 145(4):459-66. PubMed ID: 27124938
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
[TBL] [Abstract][Full Text] [Related]
12. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.
Pan J; Wu C; Xue Y; Qiu H; Chen S; Zhang J; Bai S; Wu Y; Wang Y; Shen J; Gong Y
Cancer Genet; 2014 Mar; 207(3):51-6. PubMed ID: 24699042
[TBL] [Abstract][Full Text] [Related]
13. [Report of ten cases of hematologic malignancies with idic(20q-) and literature review].
Han YS; Xue YQ; Li TY; Zhang J; Chen SN; Pan JL; Wu YF; Wang Y; Shen J
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):17-20. PubMed ID: 21429395
[TBL] [Abstract][Full Text] [Related]
14. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients.
Kurtin PJ; Dewald GW; Shields DJ; Hanson CA
Am J Clin Pathol; 1996 Nov; 106(5):680-8. PubMed ID: 8929482
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-).
Li T; Xue Y; Wu Y; Pan J
Br J Haematol; 2004 May; 125(3):337-42. PubMed ID: 15086414
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission.
Sun J; Yin CC; Cui W; Chen SS; Medeiros LJ; Lu G
Am J Clin Pathol; 2011 Mar; 135(3):391-7. PubMed ID: 21350093
[TBL] [Abstract][Full Text] [Related]
17. Acquired elliptocytosis in a patient with a myelodysplastic syndrome associated with 20q deletion.
Quiroz-Cervantes KS; Juárez-Salcedo LM; Nuevo I; Guillén H; Arbeteta J; Golbano N
Br J Haematol; 2019 Apr; 185(2):206. PubMed ID: 30592294
[No Abstract] [Full Text] [Related]
18. Deletion of chromosome 20q: friend or foe?
Hasserjian RP; Dal Cin P
Leuk Res; 2011 Jul; 35(7):844-5. PubMed ID: 21536329
[No Abstract] [Full Text] [Related]
19. [Clinical and molecular cytogenetic features of myeloid diseases characterized by i(20q-): a study of seven cases].
Li TY; Xue YQ; Wu YF; Pan JL; Liu DD; Gong SL
Zhonghua Yi Xue Za Zhi; 2004 May; 84(9):732-5. PubMed ID: 15200909
[TBL] [Abstract][Full Text] [Related]
20. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
